PMS64 Hip And Knee Arthroplasty: How Much These Procedures Impacts In The Brazilian Health Care Expenditures?  by G.T.B., Araújo et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A229 
 
 
CZP also improved household productivity and increased participation in social 
and daily activities.  
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PMS60  
THE INTRODUCTION OF BIOSIMILAR MONOCLONAL ANTIBODIES INTO 
DEVELOPED MARKETS: WHAT ARE PAYERS CONCERNED ABOUT?  
Sewak NPS, Whitcher C, Neophytou I 
Double Helix Consulting, London, UK  
OBJECTIVES: The introduction of biosimilar monoclonal antibodies into the 
market is thought to be eagerly awaited by payers. This is motivated by the need 
to constrain prescribing costs due to the ever burdening pressure on health care 
budgets. The objectives of this research were to explore payers’ attitudes 
towards the introduction of biosimiliars into the UK National Health Service, and 
to identify the key concerns of payers towards the entry of biosimilars into the 
market. As the UK is widely recognised as a leading health care market the 
outputs from this research can be applied to other developed markets. 
METHODS: A thorough literature review was carried out identifying the current 
regulatory stance and other national guidance on the introduction of biosimilar 
monoclonal antibodies. From this a series of value messages were formulated 
around four themes: the manufacture of biosimilar monoclonal antibodies, 
extrapolation of clinical data, generic substitution and interchangeability and 
pharmacovigilance. These value messages were then tested with national payers 
to identify key priority areas. RESULTS: Payers identified that interchangeability 
and pharmacovigilance were the priority areas which needed to be addressed at 
both a national and local level to manage the entry of biosimilar monoclonal 
antibodies. In particular they identified immunogenicity as a key area of concern 
due to the long acting nature of biosimilar monoclonal antibodies. They also 
recommended a greater emphasis on the use of electronic prescribing systems to 
ensure that the appropriate recording of the originator product or biosimilar is 
documented and can be traced back to an individual patient. This should be 
mandated at a national level supported by local hospital protocols. 
CONCLUSIONS: Payers are aware of the introduction of biosimilar monoclonal 
antibodies into the market. They recognise that a managed entry assisted by the 
regulatory authorities alongside locally agreed guidance will be crucial to a 
successful roll-out  
 
PMS61  
COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS WITH 
RHEUMATOID ARTHRITIS (RA) RECEIVING THEIR FIRST BIOLOGIC IN UK, 
GERMANY, FRANCE, ITALY AND SPAIN (5EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To assess the clinical characteristics of patients with RA receiving 
their first biologic in 5EU. METHODS: A multi-country multi-center medical 
chart-review study of RA patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >2RA biologic patients/week) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>5) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status. RESULTS: In 1Q2012, 2208 eligible RA patient charts were abstracted; 1562 
(71%) patients were on their first biologic (mean-age:50.7yrs, female:71%). 
Geographic distribution of patients were - UK:19%, Germany:18%, France:22%, 
Italy:23%, Spain:18%. Time-to-1stbiologic from diagnosis (range:31mo (Italy)-52mo 
(France)) and time-on-current biologic (range:17month (Italy)-27month (France)) 
differed within 5EU. The top-3 reasons for biologic treatment initiation were 
consistent across 5EU (‘mechanism of action’, ‘improve signs/symptoms’, 
‘prevent structural damage’), whereas the next 2 reasons differed (UK/Germany: 
‘disease worsened’ & ‘positive personal experience’; France: ‘inhibits disease’ & 
‘mode of administration’; Italy: ‘frequency of administration’ & ‘positive personal 
experience’; Spain: ‘positive personal experience’ & ‘inhibits disease 
progression’). Key lab measures documented were: ESR (range:20.8mm/h 
(France)-29.1mm/h (Italy)) and CRP (range:6.9mg/dl (Spain)-15.0mg/dl (UK)). 
Current disease severity per physician-judgment (mild:moderate:severe) in 5EU 
were: UK-58%:29%:13%, Germany-50%:44%:7%, France-39%:48%:12%, Italy-
47%:49%:4%, Spain-59%:36%:5%. Among patients with available data, current 
HAQ (range: 0.7(Spain)-1.5(Germany)), DAS28 (range:3.0(Spain)-3.8(Germany)), 
100mmVAS (range:23.3(France)-34.8(Italy)) and Total Sharp (range:0.9(France)-
(3.6(Germany)) differed within 5EU. CONCLUSIONS: Among RA patients receiving 
their first biologic, disease severity differed within 5EU, with patients in 
Germany with relatively higher burden. Impact of specific biologic treatments on 
the observed patterns warrants further scrutiny.  
 
PMS62  
A MULTI-COUNTRY PHYSICIAN SURVEY ON PATIENT ELIGIBILITY AND USE OF 
BIOLOGICS IN RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS) 
AND PSORIATIC ARTHRITIS (PSA) IN EUROPEAN UNION (EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To assess physician assessment of patient eligibility and eventual 
use of biologics in RA, AS and PsA in EU. METHODS: A multi-country physician 
survey was conducted in 5EU (UK, Germany, Spain, France, Italy) in RA, AS and 
PsA. Physicians were screened for experience (3-30yrs) and biologic patient 
volume (>2RA biologic patients/week, >5AS biologic patients/month, >5PsA 
biologic patients/month) and recruited from a large physician-panel to be 
geographically representative in each country. Practice characteristics, patient-
volume, physician perceptions and practice patterns were assessed; physicians’ 
target patient population was grouped into 2 categories, based on physician 
input: Group1 – patients perceived to be eligible for biologics, Group2 – patients 
who ended up receiving biologics within Group1. Summary statistics across 5EU 
are reported. RESULTS: In the first quarter 2012, 434 physicians (rheumatologists: 
97%; internist: 3%) participated in the study. Mean age: 45yrs; female: 35%; 
exclusively hospital-based practice:71%. Geographic distribution of physicians 
was: UK-18%, Germany-19%, Spain-19%, France-22%, Italy-22%. Patient volume 
per physician was: total-1065, RA-207, AS-80, PsA-88. Average frequency of 
patient encounters were: RA-11wks, AS-12wks, PsA-11wks. Physician global 
assessment of patient disease severity were (average across patients): RA mild: 
35%/moderate: 41%/severe: 23%, AS – mild: 37%/moderate: 39%/severe: 24% and 
PsA–mild: 37%/moderate:39%/severe: 24%. Physician assessment of patient 
eligibility and use of biologics were: within RA-mild-patients – Group1: 
18%/Group2: 10%, within RA-moderate-patients–Group1: 45%/Group2: 33%, 
within RA-severe-patients–Group1: 76%/Group2: 66%; within AS-mild-patients–
Group1: 20%/Group2: 11%, within AS-moderate-patients–Group1: 48%/Group2: 
37%, within AS-severe-patients–Group1: 77%/Group2: 69%; within PsA-mild-
patients–Group1: 22%/Group2: 12%, within PsA-moderate-patients–Group1: 
51%/Group2: 37%, within PsA-severe-patients–Group1: 76%/Group2: 66%; Among 
patients who received biologics, Enbrel, Humira and Remicade were the top-3 
prescribed medications across RA/AS/PsA. CONCLUSIONS: Across the markets, 
approximately one-tenth of biologic eligible patients (per physician perception) 
within corresponding disease severity groups did not end up receiving a biologic, 
across RA/AS/PsA, with the discordance slightly more pronounced within 
moderate patients. Reasons behind these patterns and the impact on subsequent 
patient outcomes warrants further scrutiny.  
 
PMS63  
VALUE-BASED INSURANCE DESIGN INFORMED BY GOVERNMENT RESEARCH: A 
CASE STUDY OF OSTEOPOROSIS FRACTURES  
Cangelosi MJ, Zhong Y, Winn A, Chambers JD 
Tufts Medical Center, Boston, MA, USA  
OBJECTIVES: To use a mixed-treatment meta-analysis and simulation model to 
estimate fracture reductions and cost savings achievable from switching 
osteoporosis patients to more efficacious treatments in a large health plan. 
METHODS: We populated the Bayesian mixed-treatment meta-analysis using 
studies identified within a recent AHRQ systematic review of anti-osteoporosis 
agents. We considered anti-osteoporosis drugs included in a health plan’s 
pharmacy benefit, i.e., alendronate, ibandronate, raloxifene, risedronate, and 
teriparatide and these drugs’ effect upon the clinical endpoints of vertebral, hip, 
and other fractures. We used the results of the meta-analysis to populate a 
stochastic simulation model to examine a cohort of 13,337 individuals with an 
osteoporosis diagnosis in a large private health plan. We compared the expected 
number of vertebral, hip, and other fractures and cost of care (drug and 
hospitalization costs) between the existing distribution of treatments as 
identified by claims data and a distribution optimized in accordance with the 
mixed-treatment meta-analysis. We obtained drugs costs from claims data and 
hospitalization costs from the literature. RESULTS: Results from the mixed-
treatment meta-analysis suggest that ibandronate and raloxifene are associated 
with worse outcomes than alendronate, risedronate, and teriparatide across the 
considered endpoints. Therefore, our simulation switched patients from 
ibandronate and raloxifene and increased the proportion of patients treated with 
alendronate, risedronate, and teriparatide. Results suggest a substantial 
reduction in clinical events and economic savings (18% reduction of clinical 
events, including a 30% reduction in new hip fractures, a 5% in vertebral 
fractures, and a 9% reduction in other fractures). We estimate total economic 
savings to the health plan of over $750 per covered patient, over $10 million in 
aggregate. CONCLUSIONS: Opportunities to leverage existing research can help 
inform value-based pharmacy benefit design. The optimized allocation of 
treatments can increase the health of beneficiaries while providing savings for 
payers.  
 
PMS64  
HIP AND KNEE ARTHROPLASTY: HOW MUCH THESE PROCEDURES IMPACTS IN 
THE BRAZILIAN HEALTH CARE EXPENDITURES?  
Araújo GTB1, Abicalaffe CL2, Savian J2, Decimoni TC1, Santos AM1, Fonseca M3 
1Axia.Bio Consulting, São Paulo, Brazil, 22iM S/A, Curitiba, Brazil, 3Federal University of São 
Paulo / Axia.Bio Consulting, São Paulo, Brazil  
OBJECTIVES: The number of hip and knee arthroplasty has been growing 
steadily over the last decade because they are effective procedures that improve 
quality of life and functional capacity and decrease pain. They have been proven 
to be cost-effective procedures in different countries. The objective of this study 
is to quantify the number and expenditure with these procedures in Brazil. 
METHODS: We used for the public health care system data from the hospital 
information system (SIH/SUS) database and for the private health care data from 
the BI2iM database that has 5 million lives. We used the codes for each of these 
two procedures as search base. All values are in 2010 Brazilian reais (US$1.00=R$ 
2.00). RESULTS: A total of 20,116 hip and 6,320 knee arthroplasties were 
performed in the public system and 20,212 hip and 16,206 knee arthroplasties 
were performed in the private health system. The total expenditure to the 
Brazilian health system generated by these procedures was R$ 584,6 millions. For 
hip procedures the expenses for the public and private systems were 
respectively R$ 60,8 millions and R$ 280 millions. For knee procedures the 
expenses for the public and private systems were R$ 15,3 millions and R$ 228, 5 
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millions. CONCLUSIONS: Hip and knee arthroplasties represents an important 
amount of investment for both public and private health care systems in Brazil. 
These are initial data to be used in future studies to determine the cost-
effectiveness and budgetary impact of different therapies linked to this 
procedure in Brazil.  
 
PMS65  
BURDEN OF DISEASE OF OSTEOARTHRITIS IN RUSSIA: RESULTS FROM 2011 
NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)  
Annunziata K1, Chapnick J2, Mould-Quevedo J3 
1Kantar Health, New York, NY, USA, 2Kantar Health, Princeton, NJ, USA, 3Pfizer, Inc., New York, 
NY, USA  
OBJECTIVES: Osteoarthritis is characterized by joint pain and mobility 
impairment associated with the gradual wearing of cartilage. Osteoarthritis 
poses a substantial and increasing burden on society as a result of impaired 
health-related quality of life and the socio-economic impact. In Russia, there are 
no solid estimates of the magnitude of the condition. This study is aimed to 
assess co-morbidity, quality of life (QOL), work/productivity loss, and medical 
resource utilization in Russian urban adults with osteoarthritis. METHODS: 
Patients’ self-reported data were collected from 2011 National Health and 
Wellness Survey (NHWS). Survey samples represented major urban areas in 
Russia. QOL was measured by the physical component score (PCS) and mental 
component score (MCS) of the Short Form-12 (SF-12). Loss of work productivity 
was measured by the Work Productivity and Activity Impairment instrument. 
Medical resource utilization was measured by health care provider, ambulance 
request and hospitalization in the past 6 months. RESULTS: Of the 10,039 adult 
respondents, 733 (7.3%) were diagnosed with osteoporosis (2.2% not diagnosed 
with osteoarthritis and 88.1% have not experienced arthritis at all). Average age 
of patients diagnosed with osteoarthritis was 54.1 years. Diagnosed osteoarthritis 
group reported more co-morbidities (sleep difficulties 51%, high blood pressure 
46%, pain 44%, insomnia 37%, arrhythmia 30%, high cholesterol 21%), lower 
mean scores of PCS (40.4 vs.47.3) and similar MCS (43.3 vs.43.8). More patients 
visited health care providers (83% vs.70%), and a higher percentage were 
hospitalized (17% vs. 9%) over the past 6 months compared to those not 
experiencing arthritis. Furthermore, osteoarthritis group reported 37.6% 
impairment in daily activity compared to 25.3% of those not experiencing 
arthritis. All mentioned differences were statistically significant (p<0.05). 
CONCLUSIONS: From Russian NHWS results, patients diagnosed with 
osteoarthritis suffer from impairment in QOL, work/productivity loss and more 
co-morbidities. Findings indicate there is still an unmet medical need in Russian 
osteoarthritis patients.  
 
PMS66  
PAYER COVERAGE ANALYSIS OF CHONDROITIN SULFATE WITH GLUCOSAMINE 
FOR OSTEOARTHRITIS IN THE UNITED STATES  
Stevens CA1, Miller KL1, Gisby M2 
1PAREXEL Consulting, Waltham, MA, USA, 2PAREXEL Consulting, Uxbridge, UK  
OBJECTIVES: American patient consumers spend in excess of $1B annually on 
drugs to treat Arthritis. Osteoarthritis is a condition that can lead to Rheumatoid 
Arthritis. This study looks at how public and private payers in the United States 
might cover the use of Chondroitin Sulfate with Glucosamine for treating 
Osteoarthritis. METHODS: Published coverage policies for products used to treat 
Osteoarthritis (OA) were gathered and analysed, along with primary data 
developed through payer interviews. Interviewees selected included pharmacy 
directors at private payers and those who administered Medicare Part D plans 
(N=3). RESULTS: Findings show that payers would provide coverage of 
chondroitin sulfate with glucosamine for Osteoarthritis if: a) The cost were less 
than $100/month; b) The Centers for Medicare and Medicaid Services (CMS) 
provides coverage; c) Data demonstrated improved outcomes over treatments 
like omega-3-acid ethyl esters and niacin tablet, film-coated extended-release. 
Payers also indicated that they would afford chondroitin sulfate with 
glucosamine with Tier 2 formulary status, similar to that of omega-3-acid ethyl 
esters and niacin tablet, film-coated extended-release. CONCLUSIONS: Based on 
our research, we believe US Medicare Part D plans and private payers would 
cover chondroitin sulfate and chondroitin sulfate with glucosamine products 
provided there is clinical data demonstrating its efficacy in OA patients, and 
assuming that CMS would approve this product as an exception to its coverage 
policy for nutritional supplements. All payers expressed that currently there are 
limited or no treatment options for OA patients, implying that a product that 
shows some statistically significant benefit will be covered and reimbursed by 
them. If clinical data shows efficacy in some or all OA patients, we believe the 
market could provide for a significant price premium as compared to current 
OTC products.  
 
PMS67  
FREQUENCY OF OUTPATIENT PHYSIOTHERAPY SERVICES IN TRAUMA 
DISEASES IN HUNGARY  
Molics B1, Kránicz J1, Schmidt B2, Sebestyén A3, Ágoston I1, Cs. Horváth Z4, Marada G1, 
Boncz I1 
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3National Health 
Insurance Fund Administration, Pécs, Hungary, 4National Institute for Quality- and 
Organizational Development in Healthcare and Medicines, Pécs, Hungary  
OBJECTIVES: The aim of our study is to assess the amount, frequency, and the 
health insurance expenses related to trauma diseases within out-patient care. 
METHODS: The data come from the financial data base of the National Health 
Insurance Fund Administration (in Hungarian: OEP) involving the year of 2009. 
The health procedure activity list was provided by the rulebook on the 
application of the activity code list in out-patient care. The trauma syndromes 
were reported in diagnosis code S00-S99. RESULTS: Trauma injuries account for 
3471657 cases in the annual number of the physiotherapy-related activities 
(32318413 cases) showing an approximately 10.5% prevalence. The 20 most 
frequent treatments accounts for 86.3 % (2997907) of total services. The following 
top-10 medical procedure were responsible for 68.14% (2365569) of total 
activities: individual training (10.95 %), muscle strengthening exercise (9.0 %), 
stretching of contractura (8.13), mobilization of joints (7.24 %), exercises against 
resistance (7.02 %), training for circulation improvement (6.4 %), exercise to 
prevention of cardiovascular complications (6.05%), passive movement of 
physical landscape (4.94%), gymnasztics (4.22%), Parts of the body per individual 
physiotherapy (4.17). Physiotherapy out-patient care for trauma patients were 3.4 
million cases with 901 million Hungarian Forint (3,2 million Euro) health 
insurance subsidy CONCLUSIONS: The 20 most commonly used activities out of 
151 with 86,3% incidence shows a varied content. The list of the 20 most 
frequent types of services reflects to the demand for the combination of active 
and passive exercises, providing an active, functional training for injured 
patients.  
 
PMS68  
AGE AND GENDER DISTRIBUTION OF OUTPATIENT CARE PHYSIOTHERAPY 
SERVICES FOR TRAUMATIC INJURIES IN HUNGARY  
Molics B1, Kránicz J1, Schmidt B2, N t L1, Vámhidy L1, Endrei D1, Zemplényi A1, Boncz I1 
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary  
OBJECTIVES: The aim of our study is to assess the utilization of out-patient care 
physiotherapy services related to trauma diseases according to age and gender. 
METHODS: The data come from the financial data base of the National Health 
Insurance Fund Administration (in Hungarian: OEP) involving the year of 2009. 
The OENO activity list was provided by the rulebook on the application of the 
activity code list in out-patient care. The trauma syndromes were reported 
according to WHO ICD diagnosis code S00-S99. We analyzed the medical 
procedures according to the Hungarian versions of the WHO “International 
Classification of Procedures in Medicine”. We analyzed the utilization of 
physiotherapy services according to age and gender. RESULTS: Trauma injuries 
account for 3471657 cases within the annual number of the physiotherapy-
related activities (32318413 cases) showing an approximately 10.5% prevalence. 
Increasing with age, the number physiotherapy procedures per 10000 population 
is on the rise with a national mean value of 3386. There is no significant 
difference between the mean values in both genders (females=3272, 
males=3349). The highest number of physiotherapy treatment is provided for the 
men patients in the age group 55 to 59 (4525) followed by age groups of 35 to 45 
with 4225 and 4272 cases. The oldest women age group show the highest value 
in this gender (7664), followed by age groups of 75 to 85 with 6057 and 6041 cases 
per 10000. The number of injury-related cases are higher in men until 49 years of 
age, but over 50 years of age is higher for women. CONCLUSIONS: In case of the 
traumatic injuries, the highest demand of the outpatient care physiotherapy 
services occurred older injured patients. The claim indicators were significantly 
higher for men and women over 50 years of age.  
 
PMS69  
DISTRIBUTION OUTPATIENT PHYSIOTHERAPY SERVICES IN THE  
DIFFERENT TRAUMA DISEASES ACCORDING TO MAJOR BODY PARTS IN 
HUNGARY  
Molics B1, Kránicz J1, Schmidt B2, Sebestyén A3, Ágoston I1, Cs. Horváth Z4, Marada G1, 
Boncz I1 
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3National Health 
Insurance Fund Administration, Pécs, Hungary, 4National Institute for Quality- and 
Organizational Development in Healthcare and Medicines, Pécs, Hungary  
OBJECTIVES: The aim of our study is to assess amount and frequency of the 
physiotherapy services in the different regions of trauma diseases within out-
patient care. METHODS: The data come from the financial data base of the 
National Health Insurance Fund Administration (in Hungarian: OEP) involving 
the year of 2009. The OENO activity list was provided by the rulebook on the 
application of the activity code list in out-patient care. The trauma syndromes 
were reported according to WHO ICD diagnosis code S00-S99. We analyzed the 
medical procedures according to the Hungarian versions of the WHO 
“International Classification of Procedures in Medicine”. The distribution of 
physiotherapy procedures were calculated accroding to major body parts. 
RESULTS: The total number of the 151 different types WHO-classified 
physiotherapy procedures was 32318413 in the year of 2009; and 3471657 (10.5%) 
of them related to trauma care with the ICD code group S00-S99. The amount 
and frequency of the physiotherapy services are in the 10 different trauma 
regions are the following: injuries of the head 57 615 (1.66%), neck 27683 (0.80%), 
thorax 67720 (1.95%), abdomen, lower back, lumbar spine and pelvis 73857 
(2.13%), shoulder and upper arm 697896 (20.10%), elbow and forearm 656537 
(18.91%), wrist and hand 466360 (13.43%), hip and thigh 353260 (10.18%), knee and 
lower leg 794326 (22.88%), ankle and foot 276403 (7.96%). CONCLUSIONS: The 
annual number of extremity injuries is the highest, while that of the torso, neck 
and head injuries is the smallest. Most cases treated in the region of the knee 
and leg, followed by the region of the upper extremity. In case of capacity 
planning for diagnostic and therapeutic procedures, these findings should be 
considered.  
 
PMS70  
USE OF BIOLOGIC AGENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 
AN ANALYSIS OF THE QUEBEC PROVINCIAL DRUG REIMBURSEMENT PROGRAM 
DATABASE  
Lachaine J1, Beauchemin C1, Desjardins O2 
1University of Montreal, Montreal, QC, Canada, 2Abbvie, St-Laurent, QC, Canada  
